ClinicalTrials.gg
Not yet recruitingNCT07743541NAPISTAR 1-03Updated Aug 5, 2026

Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy

A Phase 1/2 interventional study of TUB-040 - Dose escalation and TUB-040 - RP2D in Uterine Endometrial Cancer, sponsored by Tubulis GmbH. Not yet recruiting at 4 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Tubulis GmbH · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 715 studies in Endometrial Neoplasms with a site in United States — 196 open to participants now, 284 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Planned enrollment
219th of 591
100 · median 60
Started
2026
with 45 others
Phase 1/2
85 of 715
42 open now
Primary completion
2029-09
later than 246 of 283 live
Registered
702nd of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 219th largest by planned enrollment of the 591 interventional ones that give a count, is one of 46 that started in 2026, is one of 85 in phase 1/2, reaches primary completion later than 246 of the 283 other live ones, and was the 702nd registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

196 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

191 more — sign in →

All 196 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 355 Endometrial Neoplasms studies recruiting now, 265 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical study is to learn more about the study drug TUB-040, safety, tolerability, pharmacokinetics (PK), and effectiveness in treating patients with recurrent or progressive uterine endometrial cancer after platinum-based chemotherapy and immune checkpoint inhibitor therapy.

The primary objectives of Phase 1 of this study are to determine the safety and tolerability of TUB-040 and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D).

The primary objective of Phase 2 of this study is to evaluate the efficacy of TUB-040 monotherapy at the RP2D in endometrial cancer.

03

Conditions studied

  • Uterine Endometrial Cancer

Keywords

  • Recurrent Endometrial Cancer
  • Progressive Endometrial Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed advanced recurrent or progressive serous or endometroid endometrial cancer.

    Note: Mixed histologies are allowed if the dominant subtype is serous or endometroid.

  2. Pathological report with results of institutional MMR and/or MSI testing.
  3. Received at least 1 but no more than 3 prior lines of anticancer therapy:

    a. Must have received at least 1 line of platinum-based therapy and 1 line of programmed death ligand-1 () or programmed death-1 (PD-1) inhibitor therapy (separately or in combination) Note: Induction plus maintenance is considered as 1 . Hormonal therapy without chemotherapy will not be considered a separate line of therapy

    For dose escalation cohorts only:

    The requirement for prior treatment with a PD-1 or PD-L1 inhibitor is waived for patients enrolled in countries where treatment with these agents does not have regulatory approval for first line treatment after discussion with and approval from the Sponsor's medical monitor.

  4. Radiographic progression on or after the most recent line of anticancer therapy.
  5. Female aged ≥ 18 years at the time of consent.
  6. Disease not amenable to curative intent treatment.
  7. Radiologically by v1.1, which can include a lesion in an irradiated field that showed progression by RECIST v1.1 after irradiation.
  8. performance status of 0 or 1.
  9. > 12 weeks for disease-related mortality as evaluated by the INV.
  10. Willing to sign an release form for research purposes and determination of biomarker (eg, NaPi2b) expression. An adequate tumor tissue sample, either a formalin-fixed, paraffin-embedded (FFPE) tissue block or a minimum of 6 freshly cut, unstained sections of the most recently available tumor sample, is mandatory for biomarker assessment by the central pathology laboratory. If no archival specimens are available, a newly acquired biopsy specimen must be provided
  11. Willing to undergo a noncontrast high-resolution computed tomography (HRCT) scan of the thorax and pulmonary function testing at screening.
  12. Adequate organ function as defined by all of the following criteria (parameters must be met without growth factor or transfusion support within 4 weeks prior to enrollment):

    1. (AST)/serum glutamic oxaloacetic transaminase and alanine aminotransferase (ALT)/serum glutamic pyruvate transaminase ≤ 3.0 × the (ULN)
    2. Total serum ≤ 1.5 × ULN ( Grade ≤ 1) unless secondary to Gilbert's syndrome. Patients with Gilbert's syndrome may be included if their unconjugated bilirubin is ≤ 3 × ULN.
    3. Estimated (eGFR) > 50 mL/min calculated using the Chronic Kidney Disease Epidemiology Collaboration formula (Appendix B)
    4. Alkaline phosphatase (ALP) \< 2.5 × ULN, except if there is an alternative explanation for ALP elevation other than hepatic failure, such as the presence of bone
    5. ≥ 9.0 g/dL
    6. ≥ 1500/mm3
    7. count ≥ 100,000/mm3
    8. (INR) ≤ 1.5 and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN in the absence of anticoagulation therapy. If patients are on anticoagulation therapy, INR should be within the therapeutic range for the medical indication
  13. Resolution of all AEs from prior therapy or surgical procedures to Grade ≤ 1 or to baseline (exceptions included alopecia, hyperpigmentation or discoloration of the skin and nails [including vitiligo], stable immune-related toxicity such as hypothyroidism for patients on hormone replacement or treatment with prednisone, or equivalent, of ≤ 10 mg daily, and Grade 2 peripheral sensory neuropathy after prior treatment with taxane or other anticancer therapy).
  14. Women of (WOCP) must have a negative serum pregnancy test during screening and be neither breastfeeding or intending to become pregnant during study participation. A female will be considered to be of childbearing potential following menarche unless they have undergone permanent sterilization (ie, hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) or are . Postmenopausal is defined as at least 12 months without menses with no other medical reason (eg, chemical menopause due to anticancer treatment).
  15. For WOCP, agreement must be provided to use a medically approved, highly effective method from the time of screening throughout the study and for 6 months after the last administration of study treatment.
  16. Ability to understand, give written , comply with all study-related procedures, medication use, and assessments.
  17. No history of noncompliance with medical regimens or considered, in the opinion of the INV, to be potentially unreliable and/or uncooperative.
  18. Willing to sign and date the ICF

Exclusion criteria

Exclusion Criteria:

  1. Unresolved bowel obstruction, including radiographic findings consistent with bowel obstruction plus clinical signs and symptoms of obstruction such as nausea and/or vomiting.
  2. Prior thoracocentesis for therapeutic drainage of malignant effusion within 4 weeks prior to initiation of study treatment.
  3. Paracentesis for therapeutic drainage of malignant effusion within 4 weeks prior to initiation of study treatment.
  4. Receiving total parenteral nutrition.
  5. Serum albumin \< 2.5 g/dL (patients should not receive IV albumin within 4 weeks prior to testing).
  6. Known active central nervous system and/or carcinomatous meningitis. Note: Previously treated allowed if follow-up brain imaging after CNS directed therapy shows no evidence of progression, and they have been off for > 4 weeks prior to first dose.
  7. Pregnant, lactating, or breastfeeding.
  8. History of to exatecan or of the TUB-040 formulation.
  9. Prior treatment with an ADC-containing Topo-1 inhibitor payload. ADCs with other payloads are allowed (eg, monomethyl auristatin E, monomethyl auristatin F).
  10. Discontinuation of the most recent systemic anticancer therapy due to hematologic toxicity.
  11. Participation in any interventional clinical studies either concurrently or within 28 days or 5 half-lives (whichever is shorter) prior to enrollment of any pharmacologic agent, imaging materials, including dyes, investigational surgical techniques, or devices.
  12. Chemotherapy or other anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to initiation of study treatment.
  13. Radiotherapy \< 2 weeks prior to enrollment. Patients with wide-field radiotherapy (> 30% of marrow-bearing bone) must not have had treatment within 4 weeks prior to initiation of study treatment.
  14. Major surgery within 21 days prior to signing ICF unless the patient has recovered at that time.

    Note: Major surgery involves opening of a body cavity such as the thorax or abdomen. A lymph node or skin is not considered major surgery. Minor surgical procedures such as central venous catheter placement, tumor biopsy, and feeding tube placement are not considered major.

  15. Active ILD/pneumonitis or history of noninfectious ILD/pneumonitis/radiation pneumonitis that required steroid treatment.
  16. Oxygen saturation of \< 93% on room air at rest
  17. Resting > 470 msec. If a single QTcF is > 470 msec, the patient may enroll if the mean QTcF from 3 (ECGs) is \< 470 msec.
  18. History of nephrotic syndrome or proteinuria Grade ≥ 2.
  19. Active corneal disease, or history of corneal disease within 4 months prior to enrollment.
  20. Active, uncontrolled or severe impairment of the urogenital, renal, hepatobiliary, cardiovascular, respiratory, gastrointestinal, neurologic, or hematopoietic systems which, in the opinion of the INV, would predispose the patient to the development of complications from the administration of protocol therapy.
  21. History of another with ongoing treatment or not yet free from disease for 2 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome.
  22. Documented other concurrent nonmalignant comorbidities such as unstable or uncontrolled pectoral angina, myocardial infarction during the last 6 months, valvular heart disease that requires treatment, acute myocarditis, or congestive heart failure ( III or IV).
  23. Any concurrent anticancer chemotherapy, radiotherapy (palliative radiation may be permitted after approval by the sponsor in accordance with protocol), hormonal therapy, immunotherapy, corticosteroid therapy other than that permitted in protocol), or any other prohibited medications as listed in protocol.
  24. within 30 days prior to study enrollment.
  25. Concomitant use of strong inhibitors or strong inducers of cytochrome P450 (CYP)3A4.
  26. For Phase 1 only: Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure with reduced or severe diastolic dysfunction, potential for torsades de pointes, congenital long QT syndrome.
  27. Positive for surface antigen (HbsAg) or hepatitis B (HBV) DNA.
  28. Active acute or chronic infection.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Phase 1: Dose Escalation of TUB-040

    Participants will receive escalating doses of TUB-040 to determine recommended Phase 2 dose (RP2D).

    Drug: TUB-040 - Dose escalation

  • Experimental
    Phase 2: Monotherapy of TUB-040

    Participants in Phase 2 will receive the recommended dose of TUB-040 monotherapy determined in Phase

    Drug: TUB-040 - RP2D

Interventions

  • TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle.

  • TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle. Dose based on the RP2D

06

What researchers measure

Primary outcomes

  1. Phase 1: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Incidence and severity of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 3 years

  2. Phase 1: Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs)

    Incidence of dose-limiting toxicities (DLTs) at each dose level

    Time frame: Up to 3 years

  3. Phase 2: Overall Response Rate (ORR)

    Investigator (INV) assessment of overall response rate (ORR) by Response Evaluation Criteria for Solid Tumors (RECIST) v1.1

    Time frame: Up to 3 years

Secondary outcomes

  1. Phase 1: Overall Response Rate (ORR)

    Investigator (INV) assessment of overall response rate (ORR) by Response Evaluation Criteria for Solid Tumors (RECIST) v1.1

    Time frame: Up to 3 years

  2. Phase 1: Duration of Response (DOR)

    Investigator (INV) assessment of duration of response (DOR) by Response Evaluation Criteria for Solid Tumors (RECIST) v1.1

    Time frame: Up to 3 years

  3. Phase 1: Progression-Free Survival (PFS)

    Investigator (INV) assessment of progression-free survival (PFS) by Response Evaluation Criteria for Solid Tumors (RECIST) v1.1

    Time frame: Up to 3 years

  4. Phase 1: Disease Control Rate (DCR)

    Investigator (INV) assessment of disease control rate (DCR) by Response Evaluation Criteria for Solid Tumors (RECIST) v1.1

    Time frame: Up to 3 years

  5. Phase 1: Overall Survival (OS)

    Overall Survival (OS)

    Time frame: Up to 3 years

  6. Phase 1: Change From Baseline in Fridericia's Corrected QT interval (QTcF)

    Change from baseline in QTcF

    Time frame: Up to 3 years

  7. Phase 1: Pharmacokinetic (PK) parameter: Cmax

    Cmax is defined as: Maximum plasma/serum concentration (Cmax)

    Time frame: Up to 3 years

  8. Phase 1: Pharmacokinetic (PK) parameter: Tmax

    Tmax is defined as: Time to Cmax

    Time frame: Up to 3 years

  9. Phase 1: Pharmacokinetic (PK) parameter: AUC

    AUC is defined as: Area under the concentration time curve (AUC)

    Time frame: Up to 3 years

  10. Phase 1: Pharmacokinetic (PK) parameter: t1/2

    t1/2 is defined as: If data collected allows estimated half-life

    Time frame: Up to 3 years

  11. Phase1/Phase2: Percentage of Participants Who Develop Anti-TUB-040 Antibodies as appropriate

    Number and percentage of patients who develop anti-TUB-040 antibodies and a semiquantitative assessment of titer

    Time frame: Up to 3 years

  12. Phase 2: Durability of Response (DOR)

    Investigator (INV) assessment of durability of response (DOR) by Response Evaluation Criteria for Solid Tumors (RECIST) v1.1

    Time frame: Up to 3 years

  13. Phase 2: Progression-Free Survival (PFS)

    Investigator (INV) assessment of progression-free survival (PFS) by Response Evaluation Criteria for Solid Tumors (RECIST) v1.1

    Time frame: Up to 3 years

  14. Phase 2: Disease Control Rate (DCR)

    Investigator (INV) assessment of disease control rate (DCR) by Response Evaluation Criteria for Solid Tumors (RECIST) v1.1

    Time frame: Up to 3 years

  15. Phase 2: Overall Survival (OS)

    Overall Survival (OS)

    Time frame: Up to 3 years

  16. Phase 2: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Incidence and severity of treatment emergent adverse events (TEAEs)

    Time frame: Up to 3 years

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2029, 35 months later.

Of 80 phase 1/2 interventional studies under Endometrial Neoplasms, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 106. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2026
First posted
Aug 4, 2026
StartEst.
Oct 2026
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07743541
Lead sponsor
Tubulis GmbH
Responsible party
Sponsor
First posted
Aug 4, 2026
Start date
Oct 2026 (estimated)
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Aug 5, 2026

Study contacts

Tubulis Clinical Trial Inquiries
Contact
ct-inquiries@tubulis.com
+49 175 800 5594
Tubulis Medical Director
study director · Tubulis GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-NaPi2b/Exatecan Antibody-drug Conjugate TUB-040

Start the discussion